Accelerate Growth in the $1.72 Trillion Pharmaceutical Industry
Building a More Scalable and Resilient Pharmaceutical EcosystemAccess the Full Analysis
The pharmaceutical industry is experiencing a major shift. Demand for GLP-1 treatments, antibody-drug conjugates, and other next-generation therapeutic modalities are rising fast, and companies are racing to keep up. At the same time, they're navigating additional pressure: tighter pricing environments, stretched manufacturing capacity, and customers who expect both speed and reliability.
Our latest analysis examines how pharmaceutical companies and contract development and manufacturing organizations (CDMO) are responding to these shifts. From sterile fill-finish expansion and multisite manufacturing networks to investments in highly potent active pharmaceutical ingredient production and bioconjugation capabilities, the industry is making important moves to strengthen resilience and prepare for the next wave of growth.
Are you prepared to improve speed, scale, and supply reliability in an increasingly competitive pharmaceutical environment?
What You’ll Find in Frost & Sullivan’s Latest Analysis
How leading companies are expanding capacity while protecting supply continuity, commercialization readiness, and long-term scalability.
How digital quality systems, scalable biologics manufacturing, AI-enabled development models, and leaner clinical pathways are reshaping pharmaceutical operations.
Why CDMO collaboration, multisite manufacturing strategies, specialized fill-finish capacity, and advanced modality capabilities are becoming central to growth planning.
How pricing reform pressures in developed markets, along with manufacturing localization strategies in China and India, are reshaping the global competitive map.
This analysis covers the competitive shifts, regional developments, and growth opportunities expected to define the pharmaceutical industry through 2031.